Realistic expectations: where pharmaceutical sponsors should deploy human vs. technological resources in the digital age while running clinical trials

Available On-demand.

COVID-19 has highlighted the need for data-driven decision making and processes in both healthcare and clinical research. A.I. has tremendous potential to solve for predictive analytics, genomics, biomarker research, patient outcomes, and drug discovery. Can it meet the prescriptive and deterministic needs of running a clinical study? If not, what parts of the clinical operations process can be disrupted with technological advancement? What human-habit barriers exist and how can we change these predispositions that serve as barriers to technological advancement?

Learning Objectives:


Wendi Lau
Senior Director, Clinical Development Operations, TA Lead Specialty Medicine

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Vice Chancellor for Translational Medicine and Science
Rutgers University

Eirini Schlosser
CEO & Chairman
Dyania Health



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
marcus evans online events

We reflect on some of our best online events and reveal valuable and tangible insights on trending topics across a variety of industries.